Market news

Landry Brings Two Decades of Medtech and Public Company Finance ExperienceMINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced. Mr. Landry will

CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.

MINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. Devoted Health, a national health insurance company with the eighth largest Medicare Advantage enrollment i

Jorey Chernett, Founder of Pointillist Family Office and beneficial owner of more than 5.5% of the outstanding shares of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRx), today delivered a letter to the CVRx Board of Directors (the "Board"), urging it to launch an immediate and formal process to sell the Company to a strategic acquirer.

Detailed price information for Humana Inc (HUM-N) from The Globe and Mail including charting and trades.

CVRx (NASDAQ:CVRX) outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity’s 46th Annual Growth Conference. President and CEO Kevin Hykes sa

Detailed price information for Cvrx Inc (CVRX-Q) from The Globe and Mail including charting and trades.

2026-08-11. The following slide deck was published by CVRx, Inc.

Robert John to Depart as Chief Revenue Officer; Paul Verrastro Named Interim Head of SalesMINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that Robert John, Chief Revenue Officer, will depart the company, and that Paul Verrastro will assume the role of Interim Head of Sa

CVRx stock sinks after hours after lowering full-year revenue outlook despite revenue growth.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The Company's presentation will begin at 1:00 p.m. (ET). A live webcast of the event can be

MINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same